Survodutide

Survodutide — frequently asked questions

• What is Survodutide?

  Survodutide (BI 456906) is a long-acting peptide that co-activates GLP-1 and glucagon receptors, designed to deliver robust body-weight reduction by coupling GLP-1–mediated appetite control with glucagon-driven increases in energy expenditure and hepatic lipid mobilization.

• What is the half-life of Survodutide?

  Survodutide has an approximate half-life of Approximately 1 week (supports once-weekly dosing). The half-life determines how often you need to inject to maintain steady blood levels — use the Peptides Calculator half-life calculator to plot your specific dosing schedule and see the decay curve.

• How is Survodutide administered?

  Survodutide is typically delivered via once-weekly subcutaneous injection. The Peptides Calculator app helps you reconstitute the vial with bacteriostatic water, calculate your exact dose in syringe units, and track each injection.

• How does Survodutide work?

  Agonism at GLP-1R enhances glucose-dependent insulin secretion, slows gastric emptying, reduces appetite, and suppresses inappropriate glucagon; concurrent GCGR activation increases energy expenditure and promotes fatty-acid oxidation. The combined signaling can yield greater weight loss than GLP-1–only agonism.

• What are the researched benefits of Survodutide?

  Studied benefits of Survodutide include: Clinically meaningful body-weight reduction (once-weekly dosing), Improved glycemic and cardiometabolic markers in study populations, Reductions in liver fat and MASH-related biomarkers in trials, Potential improvements in waist circumference and lipid parameters. These are research findings only — Peptides Calculator does not provide medical advice; consult a qualified healthcare professional before starting any peptide protocol.

• What are the side effects of Survodutide?

  Reported side effects of Survodutide include: Class-typical GI effects (nausea, vomiting, diarrhea/constipation), Decreased appetite, Injection-site reactions, Possible mild heart-rate increase (glucagon component, dose-dependent), Rare: gallbladder disease or pancreatitis (incretin class consideration). Always discuss potential side effects with a licensed healthcare provider before using any research peptide.